Enzymotec (ENZY) Misses Q2 EPS by 4c; Trims FY16 Outlook

Enzymotec (NASDAQ: ENZY) reported Q2 EPS of $0.04, $0.04 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $15 million versus the consensus estimate of $14.9 million.

GUIDANCE:

Enzymotec sees FY2016 EPS of $0.25-$0.30, versus the consensus of $0.29. Enzymotec sees FY2016 revenue of $52-56 million, versus the consensus of $60.0 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
• MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c